Neurona Therapeutics | NRTX-1001 Inhibitory Neuron Cell Therapy
Neurona is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected cells, and rebalance dysregulated …
Cell therapy biotech bags $102M to fund phase 3 epilepsy plans
Apr 3, 2025 · Neurona has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
Neurona Doses First Patient in CIRM-Funded Bilateral Epilepsy …
Jun 20, 2025 · The new bilateral trial builds on encouraging results from Neurona’s ongoing trial—which observes seizures that originate from one side of the brain—and is also funded …
Neurona raises $102m to advance cell therapy for drug-resistant ...
Apr 3, 2025 · Neurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for drug-resistant mesial …
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001
Apr 3, 2025 · Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapy product candidates with the potential to provide long-term targeted repair of the nervous …
Mission | Leadership | Investors | Neurona Therapeutics
Neurona was founded by leading-edge neuroscientists and stem cell pioneers at the University of California, San Francisco. Based on nearly two decades of research, we believe that specific …
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell ...
Jun 18, 2025 · Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapies with the potential to provide long-term targeted repair of the nervous system following a single …
Latest News and Events for Neurona Therapeutics
Aug 25, 2025 · Latest News and Events for Neurona Therapeutics; a clinical-stage company focused on discovering and developing allogeneic neural cell therapies to treat chronic …
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell ...
Jun 18, 2025 · Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapies with the potential to provide long-term targeted repair of the nervous system following a single …
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001
Jun 18, 2025 · Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapies with the potential to provide long-term targeted repair of the nervous system following a single …